At the moment, there is no specific data on the efficacy of these agents in post-allo-HCT patients, but they have demonstrated a favorable safety profile to date that suggests the potential for menin inhibitors to achieve similar success for post-transplant relapse in KMT2A-rearranged and NPM1-mutated AML as FLT3 and IDH inhibitors in their respective subtypes. This evidence concerns the gene NPM1 and acute myeloid leukemia.